Anticoagulation with apixaban without stenting successfully managed cardioembolic STEMI in a 61-year-old male with atrial fibrillation and polycythemia vera, with no recurrent events at four weeks.
Case Report (n=1)
No
61-year-old male with paroxysmal atrial fibrillation (CHA₂DS₂-VASc score of 0), hypothyroidism, obstructive sleep apnea, and polycythemia vera presenting with anterolateral STEMI.
Anticoagulation (heparin infusion transitioned to apixaban 5 mg oral twice daily) without coronary stenting, and discontinuation of dual antiplatelet therapy.
Recurrent chest pain, arrhythmia, or thromboembolic events at short-term follow-up.hard clinical
Early recognition of cardioembolic STEMI in patients with hypercoagulable states allows for the avoidance of unnecessary coronary stenting and guides appropriate long-term anticoagulation.
ST-elevation myocardial infarction (STEMI) is most commonly caused by acute atherosclerotic plaque rupture with superimposed thrombosis. Coronary embolism represents a rare but clinically important non-atherosclerotic mechanism of STEMI, which is frequently associated with atrial fibrillation and other prothrombotic conditions. Embolic STEMI has been associated with higher rates of adverse outcomes and requires a management strategy distinct from atherosclerotic disease. We present a 61-year-old male with paroxysmal atrial fibrillation and polycythemia vera who presented with anterolateral STEMI. Coronary angiography revealed occlusion of the distal left anterior descending and diagonal branches without underlying atherosclerosis, consistent with a cardioembolic etiology. He was managed with anticoagulation without stenting and discharged on long-term oral anticoagulation. This case highlights the importance of considering coronary embolism in patients with arrhythmias or hypercoagulable states presenting with STEMI. Early recognition allows avoidance of unnecessary coronary stenting, guides appropriate anticoagulation, and supports targeted strategies to prevent recurrent thromboembolic events.
Building similarity graph...
Analyzing shared references across papers
Loading...
Sankalp Acharya
Monmouth Medical Center
Vyoma Patel
Maimonides Medical Center
Sai Shahane
Monmouth Medical Center
Cureus
Building similarity graph...
Analyzing shared references across papers
Loading...
Acharya et al. (Wed,) conducted a case report in 61-year-old male with paroxysmal atrial fibrillation and polycythemia vera presenting with ST-elevation myocardial infarction (n=1). Anticoagulation with apixaban was evaluated on Prevention of recurrent thromboembolic events and management of cardioembolic STEMI. Anticoagulation with apixaban without stenting successfully managed cardioembolic STEMI in a 61-year-old male with atrial fibrillation and polycythemia vera, with no recurrent events at four weeks.
synapsesocial.com/papers/69abc0925af8044f7a4e9546 — DOI: https://doi.org/10.7759/cureus.104668